How Tissue-Based Approaches Are Enabling Long-Term Implants
A new class of medical devices that integrate directly with the body’s own tissue is emerging, promising longer functional lifespans and fewer replacement surgeries. John Schorgl, CEO of Peytant Solutions, explains how tissue‑based designs improve implant stability, promote natural healing, and shift focus from electronic durability to biological compatibility. The approach leverages bioactive coatings and scaffold technologies to encourage cellular integration. Industry observers see this as a potential game‑changer for chronic‑care implants and surgical economics.
Subcutaneous Furosemide Aids With Earlier Discharge: SUBCUT II HF
A randomized SUBCUT II HF trial in 22 UK hospitals showed that subcutaneous furosemide delivered via a minipump enables safe early discharge for heart‑failure patients. The early‑discharge arm reduced average hospital stay from 11.0 to 5.6 days and added four additional days...
BIOTECanada Statement on Canada–Mexico Life Sciences Collaboration
BIOTECanada signed two memoranda of understanding with Mexico’s Asociación Mexicana de Laboratorios Farmacéuticos (AMILAF) and La Cámara Nacional de la Industria Farmacéutica (CANIFARMA), marking a new phase of life‑sciences collaboration. The MoUs were part of Mexico’s trade mission to Canada,...
A New Hantavirus Vaccine Is in the Works
Moderna announced that it is co‑developing an mRNA‑based hantavirus vaccine with Korea University’s Vaccine Innovation Center, a partnership that began in 2023. The effort follows a deadly outbreak on a Dutch cruise ship that killed three passengers and highlighted the...
FDA Alerts Health Care Providers and Patients About Increased Risk of New Blood Cancers with Tazverik (Tazemetostat) Use; Sponsor to...
The FDA has announced a voluntary market withdrawal of Tazverik (tazemetostat) after a Phase 1b/3 SYMPHONY‑1 trial revealed a 5.7% incidence of hematologic second primary malignancies (SPMs) in treated patients, compared with none in the control arm. The drug, approved in...
Is Longevity a $1.2 Quadrillion Opportunity?
Peter Diamandis released the 2026 Longevity Metatrend Report, a free 200‑page analysis of the rapidly advancing health‑span sector. The report highlights breakthroughs such as human trials of partial epigenetic reprogramming, AI‑engineered proteins achieving 50‑fold efficacy gains, and the first pig‑organ...
Dave Asprey Says Trump’s Psychedelics Order Could Reshape Men’s Mental‑health Biohacking
Biohacking pioneer Dave Asprey hailed President Donald Trump’s executive order to accelerate FDA review of psychedelic breakthrough therapies, saying it could finally give men a science‑backed way to break through stress and trauma. The move, he argues, shifts the biohacking...
Inactivity Imprints Molecular Memory in Muscle, Aging Amplifies Damage
A study in Advanced Science reveals that periods of disuse leave a lasting molecular memory in skeletal muscle. Young adults develop a protective transcriptional response, while aged muscle shows amplified atrophy and mitochondrial dysfunction, a finding that could reshape biohacking...
FDA Issues Final Guidance on Post‑Approval Pregnancy Safety Data Collection
The U.S. Food and Drug Administration released final industry guidance on how drug sponsors should collect post‑marketing safety data for pregnant patients. The framework outlines registry design, real‑world evidence methods, and statistical standards, aiming to fill long‑standing data gaps and...
Advancing Aseptic Precision: How Modern Filling Lines Elevate Sterility, Flexibility, and Throughput
Modern pharmaceutical filling lines are adopting isolator‑based, fully automated systems that integrate washing, sterilization, filling, sealing, and environmental control. Automation and AI‑driven analytics are boosting sterility assurance, reducing human intervention, and meeting stricter EU GMP Annex 1 and FDA requirements. These...
Advancing Generic Drug Development: Bioequivalence Challenges for Patient-Centric Oral Formulations - 06/11/2026
The FDA’s Center for Drug Evaluation and Research hosted a two‑day workshop on June 11, 2026 to address bioequivalence challenges in patient‑centric oral generic drugs, including pediatric formulations. Experts discussed development hurdles for chewable tablets, orally disintegrating tablets, granules, suspensions, and sublingual...
Genomic Evidence Confirms Natural Evolution (Variance) of Andes Hantavirus
A Swiss passenger infected on the MV Hondius cruise ship was found to carry an Andes hantavirus strain that is a direct descendant of a 2018 Argentine case. Whole‑genome sequencing revealed 98.7‑99% identity to the 2018 isolate and a mutation...
Diuretic Resistance Score Confirms TRANSFORM-HF’s Message
A post‑hoc analysis of the TRANSFORM‑HF trial applied the BAN‑ADHF risk score to identify patients at high risk of diuretic resistance. About 21% of the 2,421 participants scored above 12, indicating a markedly worse prognosis with 79% higher mortality and...
European Regulators Approve First‑In‑Human GLP‑1 Gene Therapy Trial for Fractyl Health
Fractyl Health received European regulatory approval to begin the first human trial of its GLP‑1 gene therapy, a novel approach that could replace chronic GLP‑1 injections. The clearance marks the inaugural clinical test of this gene‑editing strategy in Europe and...
In the Clinic for May 11, 2026
BioWorld’s May 11, 2026 “In the Clinic” roundup aggregates the day’s most relevant biopharma and med‑tech snapshots, special reports, and infographics. The page links to data‑driven analyses covering topics from mRNA vaccine research and China’s GLP‑1 landscape to pulsed‑field ablation for atrial...
An Ancient Hibernation Switch Lives in Your DNA—And Scientists Are Tapping Into Its Power
Scientists have identified ancient cis‑regulatory DNA switches that enable hibernating mammals to shut down and restart metabolism safely, and they found the same genetic circuitry embedded in the human genome. The finding comes from two new studies published in Science...
New Home for Novo's Parkinson's Cell Therapy; GSK's Deal to Sell Drug in China
Novo Nordisk has transferred its early‑stage Parkinson's disease cell therapy to a specialized biotech partner, allowing the pharma giant to offload development risk while retaining royalty rights. GSK secured a distribution agreement to launch its flagship drug in China, opening...
RegVelo AI Model Predicts Cell Fate, Tackles Developmental Disorders and Cancer
Researchers at the Stowers Institute unveiled RegVelo, an AI framework that fuses RNA‑velocity dynamics with gene‑regulatory network inference to map cell‑state transitions over time. In zebrafish neural‑crest development the model pinpointed tfec as an early pigment‑cell driver and discovered a...
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
CEL‑SCI Corp. has signed a strategic partnership with Saudi firm Amarox to register, commercialize, and distribute its immunotherapy Multikine in Saudi Arabia, with a 50/50 revenue‑sharing model. Amarox will act as the local regulatory representative, seeking the Saudi Food and...
OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic’s Aptima HPV Assay
OM1’s AI‑driven real‑world evidence platform underpinned a landmark FDA submission that cleared Hologic’s Aptima HPV assay for primary cervical cancer screening. The study aggregated data from more than 650,000 women across U.S. health systems, automating extraction from electronic health records...
Avenacy Announces Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection in the U.S. Market
Avenacy, a specialty injectable drug company, has launched a ready‑to‑use Tranexamic Acid 0.7% Sodium Chloride Injection in the United States. The product mirrors the active ingredient of Pfizer’s CYKLOKAPRON® and is indicated for short‑term use in hemophilia patients undergoing tooth...
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors
HistoSonics has filed a De Novo request with the FDA to expand its Edison® Histotripsy System from liver to kidney tumor treatment. The submission is backed by the ongoing HOPE4KIDNEY trial, which has enrolled 67 patients and shows precise, non‑invasive tumor...
Inhibrx Says Combo Therapy Shrank More Tumors than Merck's Keytruda Alone
San Diego‑based biotech Inhibrx reported that its experimental antibody INBRX‑106, when paired with Merck’s immunotherapy Keytruda, produced a higher rate of tumor shrinkage than Keytruda alone in patients with metastatic head and neck squamous cell carcinoma. The early‑stage study enrolled...
Therorna to Showcase Clinical-Ready Circular RNA in Vivo CAR-T and CircRNA Pipeline at the 2026 American Society of Gene &...
Therorna Inc. will present three posters at the 2026 ASGCT meeting, highlighting its lead in‑vivo CAR‑T candidate TI‑0032, a circRNA‑encoded CD19×CD3 T‑cell engager, and the HPV16 therapeutic vaccine TI‑0093. TI‑0032 has just entered a first‑in‑human investigator‑initiated trial for refractory autoimmune...
Internal Nanobodies Tackle Cystic Fibrosis
Researchers have engineered a cell‑penetrating nanobody that enters airway cells and stabilizes the misfolded CFTR protein responsible for cystic fibrosis. By fusing the nanobody to a ten‑arginine peptide, the hybrid molecule crosses the cell membrane and restores up to 90%...
Ocrevus Slows Disability Progression in Advanced PPMS, Trial Finds
A Phase 3 ORATORIO‑HAND trial involving more than 1,000 adults with primary progressive multiple sclerosis (PPMS) showed that Ocrevus (ocrelizumab) significantly slows disability progression. Over a median follow‑up of nearly three years, the drug reduced the risk of confirmed disability...
Researchers Develop Body-Compatible Dermal Electrode
Researchers at POSTECH have created a dermal bioelectrode that inserts like a microneedle but becomes soft in the dermis, eliminating immune response. The electrode’s effervescent sacrificial layer enables rapid penetration and then transforms to a flexible structure, delivering stable biosignal...
Tech Advances Redefine IVF and Our View of Reproduction
Tech advances not only made IVF safer and more effective; they fundamentally changed the way we think about our reproduction.
US Government Spends Hundreds of Millions on Biotech Pilot Plants as National Security Priority
The U.S. government is pouring hundreds of millions of dollars into BioMADE, a public‑private consortium aimed at scaling bio‑manufacturing for food, defense and industrial applications. Since its 2021 launch, BioMADE has secured $87 million from the Department of Defense (DoD), $450 million...
Ocrelizumab Preserves Ambulation, Hand Function in MS
A six‑year analysis of the ENSEMBLE trial shows that early‑stage relapsing‑remitting multiple sclerosis patients treated with ocrelizumab largely maintained functional ability. 86.1% preserved normal ambulation and 93% kept normal hand dexterity throughout the study, while 34% of those with baseline...
Braveheart Bio's Hengrui-Licensed Cardiac Drug Scores Second Clinical Win
Braveheart Bio announced that its heart‑muscle therapy, licensed from China’s Jiangsu Hengrui Pharmaceuticals, achieved its primary endpoint in a mid‑stage (Phase 2) trial for heart failure with reduced ejection fraction. The study reported an 8% absolute improvement in left‑ventricular ejection fraction...
Drug Repurposing
The FDA has issued a request for public comment on drug repurposing, seeking input from patients, clinicians, and researchers on priority disease areas and candidate drugs. The initiative builds on existing programs such as Project Renewal, which updates oncology drug...
The Next Frontier for Hantavirus: Finding Vaccines and Treatments
A hantavirus outbreak on a cruise ship has killed three people and sickened several others, marking the first documented person‑to‑person transmission of the disease. The strain’s heightened transmissibility has revived interest in vaccine and therapeutic candidates that were previously shelved...
Late Line RCC: Where Darlifarnib Fits and Why LITESPARK-012 Matters
At the International Kidney Cancer Symposium, Kura presented phase 1 data showing its next‑generation farnesyl transferase inhibitor darlifarnib combined with cabozantinib achieved a 44% objective response rate in clear cell renal cell carcinoma patients previously treated with cabozantinib. The cohort was...
FDA Embraces AI: Radiology Leads 1,400 Approvals via 510(k)
The FDA, a global leader in healthcare regulation, is adapting its framework to include AI-based medical devices, with 1400 approvals and clearances to date, indicating an acknowledgment of AI’s expanding role in healthcare. Radiology leads in AI device approvals reflecting deep...
Fractyl Secures Dutch CTA for First GLP‑1 Gene Therapy Trial
Fractyl Health today announced that it has received Clinical Trial Application (CTA) authorization in the Netherlands to initiate the Phase 1/2 first-in-human study of RJVA-001 - $GUTS first clinical candidate from its Rejuva 🧵👇 GLP-1 Gene Therapy platform and the...
Naked Mole‑Rat Gene Extends Mouse Lifespan by 4.4%, Marking First Cross‑Species Longevity Transfer
Researchers at the University of Rochester have engineered mice to carry the naked mole‑rat version of the hyaluronan synthase 2 gene, raising high‑molecular‑weight hyaluronic acid levels and delivering a 4.4% increase in median lifespan. The study demonstrates that a longevity...
Dog Drug Flavor Loved, but Owners Smell Vomit
from the trenches of dog drug development: last week we had to change the flavoring in one of our drugs because, while the dogs LOVE it, to dog owners it smells like ........ vomit
GLP‑1 Drugs Boost Survival, Cut Recurrence in Obese Breast Cancer Patients
In women with breast cancer and obesity or T2 diabetes, a large propensity matching retrospective analysis reports association of GLP-1 drug therapy with improved survival and reduced risk of recurrence https://t.co/GjimCr97S0
Noncovalent Fragments vs WRN
Researchers at Merck and Proteros reported a noncovalent fragment‑based campaign against the Werner syndrome helicase (WRN), a synthetic‑lethal cancer target. Using a 1,020‑compound fluorine‑fragment library screened by 19F‑NMR and a separate 500‑compound SPR screen, they identified seven primary hits, three...
GNPS2 Enables Comprehensive Drug Metabolism Toolkit
Nature Protocols: A versatile toolkit for drug metabolism studies with GNPS2: from drug development to clinical monitoring https://t.co/lEejrO6gXT https://t.co/qlybcRgD9V
China Ranks Third Globally in AI-Driven Life Sciences
China ranks third in global index for AI competitiveness in life sciences China listed behind only the US and UK, reflecting the country’s ‘major scale’ in AI, biotechnology and talent, says data consortium https://t.co/IqiWdO5hea via @scmpnews
CSL Ltd Slashes FY2026 Forecast, Flags $5 B Impairments as Shares Dive 20%
Interim CEO Gordon Naylor announced that CSL Ltd now expects FY2026 revenue of about $15.2 billion and underlying net profit of $3.1 billion, down from prior guidance. The company also disclosed roughly $5 billion in additional non‑cash impairments, triggering a 20% share plunge...
QP Essentials: Reducing Risk and Delays in EU and UK Trials
Clinical trial sponsors often encounter delays when shipping supplies to the EU and UK because Qualified Persons must certify each batch. Catalent’s webinar outlines the core QP responsibilities, highlights differences between EU and UK regulations, and offers practical steps such...
Rare Disease Community Gains New Treatment Hope After Five Years
Five years after disaster, a rare disease community gets new chance at treatment Yet another heart-rending story from @Jasonmmast. https://t.co/9vgOKpInL3
FDA Grants Fast Track Designation to Zai Lab’s DLL3-Targeting ADC for epNECs
Zai Lab’s DLL3‑targeting antibody‑drug conjugate zocilurtatug pelitecan received FDA Fast Track designation for extrapulmonary neuroendocrine carcinomas (epNECs). Early‑stage data showed a 38.2% objective response rate in heavily pre‑treated patients, indicating meaningful antitumor activity. The designation promises more frequent FDA interactions,...
Study Compares Two Antibiotics in Treating Severe Hemorrhagic Bacterial Pneumonia
Researchers at Osaka Metropolitan University compared cefiderocol (CFDC) and levofloxacin (LVFX) in a mouse model of severe hemorrhagic pneumonia caused by multidrug‑resistant Stenotrophomonas maltophilia. Both drugs significantly increased survival and reduced bacterial loads in lungs and heart relative to untreated...
HIV-1 Strains Reveal Varied Paths to Antibody Escape
Scientists have mapped how HIV‑1 strains evade broadly neutralizing antibodies (bnAbs) through multiple, strain‑specific pathways. Using genomic sequencing, cryo‑EM and X‑ray crystallography, the team showed that the virus remodels its envelope glycoprotein (Env) via glycan shield alterations, loop mutations and...
Inside CSL’s Strategy to Simplify a Biotech Giant
CSL Limited is entering a strategic simplification phase, announced in August 2025, that will see its vaccine arm Seqirus spun off as a separate ASX‑listed company by the end of 2026 and a restructuring program that could cut up to 15% of...